Robert Terry, Co-Founder of U.S. Alzheimer’s Research Dies at 93

Article ID: 675872

Released: 5-Jun-2017 8:05 AM EDT

Source Newsroom: Alzforum

Newswise — An era of Alzheimer’s disease research has come to a close with the passing of Robert D. Terry in Carlsbad, California. In the early 1960s, when scientific interest in Alzheimer’s was sparse in the U.S., Terry jump-started the field with neuropathological and biochemical studies on both amyloid plaques and neurofibrillary tangles. Terry assembled an interdisciplinary group in the Bronx that became an international powerhouse of AD research in the ’60s and ’70s. (New York’s MOMA even exhibited his electron microscopy.) In 1984, he moved to one of the first five AD Research Centers set up by the NIA, at the University of California, San Diego, and there worked out how to measure neuronal loss in Alzheimer’s. Terry was among the first to realize that the loss of connections between those cells led to cognitive decline.

Terry was both beloved and tough. He parachuted into the Battle of the Bulge after enlisting in WWII at age 19; stared down mafia guards; vigorously argued his opinions in public; and was a friend of British neurologist and popular writer Oliver Sacks, who spent a season working in Terry’s lab. Read Alzforum’s obituary to learn more about the life and work of this titan in the field.

 

About Us

Founded in 1996, Alzforum is a news and information resource website dedicated to helping researchers accelerate discovery and advance development of diagnostics and treatments for Alzheimer’s disease and related disorders.

Our site expands the traditional mode of scientific communication by reporting the latest scientific findings and industry news with insightful analysis that puts breaking news into context. We advance research by developing open-access databases of curated, highly specific scientific content to visualize and facilitate the exploration of complex data. Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD.

Alzforum is supported by a team with backgrounds in science, journalism, information technology, design, and data science. Together with a distinguished Scientific Advisory Board, and the active participation of a global network of scientists, we strive to produce unbiased content to a rigorous editorial standard.

Alzforum is operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. Alzforum does not endorse any specific product or scientific approach.


Comment/Share





Chat now!